

What is the purpose of this study?

To learn if vepugratinib may be used to treat solid tumors that have a change in the *FGFR3* gene.

What is FGFR3?

- FGFR3 stands for Fibroblast Growth Factor Receptor 3
- FGFR3 is a gene that everyone has but undergoes a change in some people, resulting in cancer in the bladder, urinary tract, or other areas of the body
- To look for a change(s) in the *FGFR3* gene, a doctor will perform a test using the patient's blood and/or tumor tissue

Who can participate in the study?

This study is for patients:

- · who are 18 years or older
- diagnosed with metastatic urothelial carcinoma or another solid tumor with a change in the FGFR3 gene
- who have undergone all standard treatments for the type of cancer they have

Please look at the study website for a complete list of what is needed to participate.

What is the plan for the study?

- This is an open-label study, meaning both doctors and patients will know what treatment is being given
- All patients will receive vepugratinib. No placebo will be given in this study*



Vepugratinib

Daily oral medication

*Vepugratinib in combination with pembrolizumab, or enfortumab vedotin plus pembrolizumab may also be studied.

What is the main goal of the study?

• The main goal of the study is to learn about the safety, side effects, and effectiveness of vepugratinib Please look at the study website for a complete list of the study goals.

For more information, please visit the study website:



https://clinicaltrials.gov/ study/NCT05614739 Lilly Trials Support:

LillyTrials@lilly.com

The use of the investigational medicine is experimental.

Not all risks are known. There is no guarantee that a participant's cancer will improve when taking part in this study.

There may be multiple sites in this clinical trial. If you have further questions or interest in this clinical trial, please contact -

Telephone: 1-877-285-4559 or 1-317-615-4559

Email: LillyTrials@lilly.com

